Daiwa Securities Group Inc. I Mab Transaction History

Daiwa Securities Group Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 05, 2021	BUY	$57.18 - $84.43 $4,631 - $6,838	81 Added 128.57%	144 $10,000
Q2 2021 Aug 06, 2021	BUY	$47.86 - $83.95 $1,244 - $2,182	26 Added 70.27%	63 $5,000
Q1 2021 May 03, 2021	BUY	$44.38 - $63.97 $310 - $447	7 Added 23.33%	37 $2,000
Q4 2020 Feb 04, 2021	BUY	$32.94 - $47.15 $988 - $1,414	30 New	30 $1,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $130M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.